Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 3/20 | 0.45 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 10/20 | 0.36 |
| ▸ | DRD2 | P14416 | 9/20 | 0.36 |
| ▸ | DRD3 | P35462 | 8/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313602 | 0.85 | CALCRL (0.47) | CALCRLRAMP1CTSSNSD3DRD4 | |
| SCHEMBL12622796 | 0.83 | CALCRL (0.53) | CALCRLRAMP1CTSSCNR1CNR2 | |
| SCHEMBL12400695 | 0.83 | CALCRL (0.47) | CALCRLRAMP1CTSSNSD3DRD4 | |
| SCHEMBL13907972 | 0.83 | CALCRL (0.47) | CALCRLRAMP1CTSSNSD3DRD4 | |
| SCHEMBL439501 | 0.82 | CALCRL (0.45) | CALCRLRAMP1CTSSNSD3DRD4 | |
| SCHEMBL13801339 | 0.82 | CALCRL (0.46) | CALCRLRAMP1CTSSNSD3DRD4 | |
| SCHEMBL12219072 | 0.81 | HPGD (0.46) | CALCRLRAMP1CTSSNSD3CNR1 | |
| SCHEMBL3278017 | 0.81 | CALCRL (0.55) | CALCRLRAMP1CTSSCNR1CNR2 | |
| SCHEMBL2257145 | 0.80 | NSD3 (0.53) | CALCRLRAMP1CTSSNSD3 | |
| SCHEMBL3278151 | 0.80 | CALCRL (0.44) | CALCRLRAMP1CTSSNSD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAMP1 9/4885CTSS 802/4885 |
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | CALCRL 2/4885RAMP1 60/4885CTSS 1290/4885 |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | CALCRL 3/4885RAMP1 53/4885CTSS 1400/4885 |
| US-20120065190-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885RAMP1 9/4885CTSS 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.